Skip to main content
Top
Published in: Familial Cancer 3/2021

01-07-2021 | Breast Cancer | Short Communication

Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes

Authors: Francesca Gensini, Roberta Sestini, Alessandro De Luca, Valentina Pinna, Paola Daniele, Lorenzo Orzalesi, Maria Cristina Petrella, Berardino Porfirio, Laura Papi

Published in: Familial Cancer | Issue 3/2021

Login to get access

Abstract

We present a 24-year-old female patient affected by neurofibromatosis type 1 (NF1) who developed a malignant phyllodes tumor of the breast. The molecular studies showed that the patient carried a heterozygous inactivating deleterious variant in BRCA1 inherited from the father associated with a germline de novo pathogenic alteration in NF1; the tumor presented a biallelic inactivation of both genes. Therefore, tumor analyses helped to establish that the germline NF1 and BRCA1 variants were in cis on the paternal chromosome. This last information is important to provide adequate genetic counselling regarding the risk of recurrence in the offspring, as well as opportunity for early intervention. In conclusion, we present the first case of a malignant phyllodes tumor of the breast in patient carrying pathogenic variants in NF1 and BRCA1. Further studies will be necessary to understand if the phyllodes histotype represents a very rare component of NF1-associated breast cancer.
Literature
1.
go back to reference Cimino PJ, Gutmann DH (2018) Neurofibromatosis type 1. Handb Clin Neurol 148:799–811CrossRef Cimino PJ, Gutmann DH (2018) Neurofibromatosis type 1. Handb Clin Neurol 148:799–811CrossRef
2.
go back to reference Frayling IM, Mautner VF, van Minkelen R et al (2019) Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet 56:209–219CrossRef Frayling IM, Mautner VF, van Minkelen R et al (2019) Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet 56:209–219CrossRef
3.
go back to reference El-Zawahry MD, Farid M, Abd el-Latif A, Horeia H, el-Gindy M, Twakal G, el-Zawahry MD et al (1989) Breast lesions in generalized neurofibromatosis: breast cancer and cystosarcoma phylloides. Neurofibromatosis 2:121–124PubMed El-Zawahry MD, Farid M, Abd el-Latif A, Horeia H, el-Gindy M, Twakal G, el-Zawahry MD et al (1989) Breast lesions in generalized neurofibromatosis: breast cancer and cystosarcoma phylloides. Neurofibromatosis 2:121–124PubMed
4.
go back to reference Coffin CM, Cassity J, Viskochil D, Randall RL, Albritton K (2004) Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A 127A:40–43CrossRef Coffin CM, Cassity J, Viskochil D, Randall RL, Albritton K (2004) Non-neurogenic sarcomas in four children and young adults with neurofibromatosis type 1. Am J Med Genet A 127A:40–43CrossRef
5.
go back to reference Paul A, Paul S (2014) The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci (Landmark Ed) 9:605–618CrossRef Paul A, Paul S (2014) The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci (Landmark Ed) 9:605–618CrossRef
6.
go back to reference Campos B, Balmaña J, Gardenyes J, Valenzuela I, Abad O, Fàbregas P, Volpini V, Díez O (2013) Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer. Breast Cancer Res Treat 139:597–602CrossRef Campos B, Balmaña J, Gardenyes J, Valenzuela I, Abad O, Fàbregas P, Volpini V, Díez O (2013) Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer. Breast Cancer Res Treat 139:597–602CrossRef
7.
go back to reference Jeon YW, Kim RM, Lim ST, Choi HJ, Suh YJ (2015) Early-onset breast cancer in a family with neurofibromatosis Type 1 associated with a germline mutation in BRCA1. J Breast Cancer 18:97–100CrossRef Jeon YW, Kim RM, Lim ST, Choi HJ, Suh YJ (2015) Early-onset breast cancer in a family with neurofibromatosis Type 1 associated with a germline mutation in BRCA1. J Breast Cancer 18:97–100CrossRef
8.
go back to reference Ceccaroni M, Genuardi M, Legge F, Lucci-Cordisco E, Carrara S, D’Amico F, Greggi S, Scambia G (2002) BRCA1-related malignancies in a family presenting with von Recklinghausen’s disease. Gynecol Oncol 86:375–378CrossRef Ceccaroni M, Genuardi M, Legge F, Lucci-Cordisco E, Carrara S, D’Amico F, Greggi S, Scambia G (2002) BRCA1-related malignancies in a family presenting with von Recklinghausen’s disease. Gynecol Oncol 86:375–378CrossRef
9.
go back to reference Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, Evans DG (2007) Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 44:481–484CrossRef Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E, Evans DG (2007) Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 44:481–484CrossRef
10.
go back to reference Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E, Espín J, Sánchez MJ (2014) Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast 23:721–742CrossRef Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E, Espín J, Sánchez MJ (2014) Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast 23:721–742CrossRef
11.
go back to reference Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416CrossRef Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416CrossRef
12.
go back to reference Khan SA, Badve S (2001) Phyllodes tumors of the breast. Curr Treat Options Oncol 2:139–147CrossRef Khan SA, Badve S (2001) Phyllodes tumors of the breast. Curr Treat Options Oncol 2:139–147CrossRef
13.
go back to reference Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621–4628CrossRef Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621–4628CrossRef
14.
go back to reference Rhiem K, Flucke U, Engel C, Wappenschmidt B, Reinecke-Lüthge A, Büttner R, Schmutzler RK (2007) Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast. Cancer Genet Cytogenet 176:76–79CrossRef Rhiem K, Flucke U, Engel C, Wappenschmidt B, Reinecke-Lüthge A, Büttner R, Schmutzler RK (2007) Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast. Cancer Genet Cytogenet 176:76–79CrossRef
15.
go back to reference Rosenberger LH, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, Jacobs LK, Miller ME, Gallagher KK, Wong J, Neuman HB, Tseng J, Hassinger TE, Jakub JW (2020) Germline genetic mutations in a multi-center contemporary cohort of 550 phyllodes tumors: an opportunity for expanded multi-gene panel testing. Ann Surg Oncol 27:3633–3640CrossRef Rosenberger LH, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, Jacobs LK, Miller ME, Gallagher KK, Wong J, Neuman HB, Tseng J, Hassinger TE, Jakub JW (2020) Germline genetic mutations in a multi-center contemporary cohort of 550 phyllodes tumors: an opportunity for expanded multi-gene panel testing. Ann Surg Oncol 27:3633–3640CrossRef
16.
go back to reference Yeong J, Thike AA, Young Ng CC, Md Nasir ND, Loh K, Teh BT, Tan PH (2017) A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology 49:786–789CrossRef Yeong J, Thike AA, Young Ng CC, Md Nasir ND, Loh K, Teh BT, Tan PH (2017) A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology 49:786–789CrossRef
17.
go back to reference Nozad S, Sheehan CE, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Schrock AB, Hirshfield KM, Ali N, Ganesan S, Ali SM, Miller VA, Stephens PJ, Ross JS, Chung JH (2017) Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162:597–602CrossRef Nozad S, Sheehan CE, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Schrock AB, Hirshfield KM, Ali N, Ganesan S, Ali SM, Miller VA, Stephens PJ, Ross JS, Chung JH (2017) Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162:597–602CrossRef
18.
go back to reference Seminog OO, Goldacre MJ (2015) Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer 112:1546–1548CrossRef Seminog OO, Goldacre MJ (2015) Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer 112:1546–1548CrossRef
Metadata
Title
Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes
Authors
Francesca Gensini
Roberta Sestini
Alessandro De Luca
Valentina Pinna
Paola Daniele
Lorenzo Orzalesi
Maria Cristina Petrella
Berardino Porfirio
Laura Papi
Publication date
01-07-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2021
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00217-x

Other articles of this Issue 3/2021

Familial Cancer 3/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine